Sledge C B, Zuckerman J D, Shortkroff S, Zalutsky M R, Venkatesan P, Snyder M A, Barrett W P
Brigham and Women's Hospital, Boston, Massachusetts 02115.
J Bone Joint Surg Am. 1987 Sep;69(7):970-5.
One hundred and eleven patients who had seropositive rheumatoid arthritis and persistent synovitis of the knee were treated with intra-articular injection of 270 millicuries of dysprosium-165 bound to ferric hydroxide macroaggregates. A two-year follow-up was available for fifty-nine of the treated knees. Thirty-nine had a good result; nine, a fair result; and eleven, a poor result. Of the twenty-five knees that had Stage-I radiographic changes, nineteen had a good result. Of the thirty-four knees that had Stage-II radiographic changes, twenty showed a good result. Systemic spread of the radioactivity from the injected joint was minimum. The mean whole-body dose was calculated to be 0.3 rad and that to the liver twenty-four hours after injection, 3.2 rads. The results indicated that dysprosium-165-ferric hydroxide macroaggregate is an effective agent for performing radiation synovectomy, particularly in knees that have Stage-I radiographic changes. Because of the minimum rate of systemic spread of the dysprosium-165, it offers a definite advantage over agents that previously have been used.
111例血清反应阳性的类风湿性关节炎且膝关节持续性滑膜炎患者接受了关节腔内注射270毫居里与氢氧化铁大颗粒结合的镝-165的治疗。对59个接受治疗的膝关节进行了为期两年的随访。39个结果良好;9个结果尚可;11个结果较差。在25个有I期放射学改变的膝关节中,19个结果良好。在34个有II期放射学改变的膝关节中,20个结果良好。注射关节放射性的全身扩散最小。计算出的平均全身剂量为0.3拉德,注射后24小时肝脏的剂量为3.2拉德。结果表明,镝-165-氢氧化铁大颗粒是进行放射性滑膜切除的有效药物,尤其是在有I期放射学改变的膝关节中。由于镝-165全身扩散率最低,与以前使用的药物相比具有明显优势。